| Followers | 22 |
| Posts | 13256 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Monday, March 30, 2026 3:45:28 AM
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
March 30, 2026 3:41 AM
PR Newswire (US)
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: August 3, 2023 to December 26, 2025
DEADLINE: April 6, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Ultragenyx gave created falsely optimistic beliefs for its investors regarding the performance of its drug candidate in its Phase III trial. The Company failed to achieve statistically significant endpoints despite its optimistic communications. Based on these facts, Ultragenyx's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/ultragenyx-pharmaceutical-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--rare-302728368.html
SOURCE DJS Law Group LLP
Recent RARE News
- Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE • PR Newswire (US) • 04/06/2026 06:24:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:19:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:45:09 PM
- Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) • GlobeNewswire Inc. • 04/02/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:12:33 PM
- RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm • PR Newswire (US) • 03/31/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 12:45:08 PM
- Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy • GlobeNewswire Inc. • 03/30/2026 12:30:00 PM
- Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE • PR Newswire (US) • 03/30/2026 07:41:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/27/2026 08:31:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/27/2026 08:30:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/27/2026 08:30:23 PM
- RARE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ultragenyx Pharmaceutical Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/24/2026 01:00:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 08:30:00 PM
- RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm • PR Newswire (US) • 03/17/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:45:25 PM
- Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency • GlobeNewswire Inc. • 03/12/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:42:28 PM
- Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class Action - RARE • PR Newswire (US) • 03/10/2026 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2026 10:28:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 12:09:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 12:08:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:51:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:51:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:50:25 PM
